Full Answer
Why has Pfizer stock floundered?
Pfizer chief corporate affairs chief Sally Sussman shares lessons from how the company responded to the global pandemic. INC. TODAY'S MUST READS: New Research: Status Reports Can Make Teams Less Effective INC. TODAY'S MUST READS: How to Stay Innovative ...
Should I buy Pfizer Inc. (PFE)?
Pfizer Inc. (NYSE:PFE) released its full-year results, but the market seems to be already pricing-in a decline. Shares are down 4.4% to US$51.5 in the past week, and the stock is currently in the red. Markets are forward-looking, and the price decline ...
Where will Pfizer be in 5 years?
Pfizer’s early data showed two of the extra-low doses were safe for kids under 5 and strong enough to give good protection to babies as young as 6 months. But once tots reached the preschool age -- the 2- to 4-year-olds -- two shots didn’t rev up ...
Why is PFE dropping?
There were a couple of other factors that help explain the stock's drop. Late in the month, the company announced that it was ending the clinical development of vupanorsen, a drug thought to be a possible therapy to reduce cardiovascular risk from hypertriglyceridemia.
What happened
Shares of several top COVID-19 vaccine makers were sinking on Tuesday. Pfizer (NYSE: PFE) stock was down 2.7% as of 11:09 a.m. EDT. Shares of Pfizer's partner, BioNTech (NASDAQ: BNTX), were falling 7%. Moderna (NASDAQ: MRNA) stock was tumbling 5.4%. Novavax (NASDAQ: NVAX) was the biggest loser with its shares declining 8.1%.
So what
It's really not all that surprising that these stocks would give up much of the gains from Monday. FDA approval for the Pfizer-BioNTech vaccine was fully expected.
Now what
Pfizer, BioNTech, and Moderna hope to win EUAs for their vaccines in younger children within the next few months. The companies also will pursue full FDA approvals in these age groups. Novavax plans to file for EUA of its COVID-19 vaccine in the fourth quarter, with submissions in the U.K. and Europe coming even sooner.
The Motley Fool
Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community.
NYSE: PFE
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
NYSE: PFE
So why are these vaccine stocks tumbling today? Investors appear to be looking past the current surge in COVID-19 cases and expect a future where fewer vaccine doses are administered.
So what
Investors should always look forward. And the number of COVID-19 vaccine doses sold by Pfizer, BioNTech, and Moderna could very well decline significantly after 2022 (or perhaps 2023).
Now what
Cuba Gooding, Jr.'s character in the movie Jerry Maguire had a famous line that seems applicable for Pfizer, BioNTech, and Moderna: "Show me the money." The main thing for investors to watch with all three companies is the money -- in particular, supply deals for COVID-19 vaccines for beyond 2022.
Premium Investing Services
Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.
What is Pfizer's market cap?
Pfizer Ltd., incorporated in the year 1950, is a Large Cap company (having a market cap of Rs 26,167.47 Crore) operating in Pharmaceuticals sector. Pfizer Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services and Scrap for the year ending 31-Mar-2020.
What is face value of stock?
Face value of a stock is the value ascribed to the stock as per the balance sheet of the company. The dividend declared by a company is usually declared as a percentage of face value. (₹) -.
